Actoplus Met Patent Expiration

ACTOPLUS MET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5965584 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6166042 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6166043 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6172090 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US9101660 TAKEDA PHARMS USA Solid preparation
Jan, 2027

(2 years from now)

US9320714 TAKEDA PHARMS USA Tablet
Feb, 2029

(4 years from now)



Actoplus Met is a drug owned by Takeda Pharmaceuticals Usa Inc. It is used for improving glycemic control in patients with type 2 diabetes already on a combination of pioglitazone and metformin or a thiazolidinedione (TZD) and metformin. Actoplus Met uses Metformin Hydrochloride; Pioglitazone Hydrochloride as an active ingredient. Actoplus Met was launched by Takeda Pharms Usa in 2005. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 03, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
M(M-116) May 17, 2015

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 August, 2005

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione (tzd) and metformin or who have inadequate glycemic...

Dosage: TABLET

More Information on Dosage

ACTOPLUS MET family patents

Family Patents